Using AI to improve detection of skin cancer with imaging technology
AI-aided Optical Coherence Tomography for the Detection of Basal Cell Carcinoma
This study is testing if using artificial intelligence can help doctors more accurately detect skin cancer, specifically Basal Cell Carcinoma, by looking at special scans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 124 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Maastricht University Medical Center Academic / other |
| Locations | 1 site (Maastricht, Limbrug) |
| Trial ID | NCT05817279 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of artificial intelligence in enhancing the diagnostic accuracy of Optical Coherence Tomography (OCT) for detecting Basal Cell Carcinoma (BCC). OCT assessors will review OCT scans of BCC lesions both with and without the assistance of a clinical decision support system (CDSS) to determine if AI can improve diagnostic certainty. The study will include a total of 124 scans, comparing the confidence levels and accuracy of diagnoses made with and without AI support. The goal is to assess whether AI can lead to more reliable and non-invasive cancer detection.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have undergone both an OCT scan and a punch biopsy for an equivocal BCC lesion.
Not a fit: Patients who are unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and non-invasive diagnoses of Basal Cell Carcinoma, reducing the need for invasive biopsies.
How similar studies have performed: Other studies have shown promise in using AI to enhance diagnostic imaging, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients (18+ years) * Patient underwent OCT scan and punch biopsy for an equivocal BCC lesion Exclusion Criteria: - Patient unable to sign informed consent
Where this trial is running
Maastricht, Limbrug
- Maastricht University Medical Center+ — Maastricht, Limbrug, Netherlands (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.